TAILORx

NCT00310180 📎

Regimen

Experimental
Adjuvant chemotherapy followed by endocrine therapy for 5 years (various chemotherapy regimens per investigator).
Control
Endocrine therapy alone for 5 years.

Population

Women with HR+/HER2-/node-negative early breast cancer and Oncotype DX 21-gene Recurrence Score (RS) 11-25 (mid-range), randomized to chemoendocrine therapy or endocrine therapy alone.

Key finding

TAILORx definitively established that most postmenopausal women with HR+/HER2-/N0 disease and RS 11-25 can safely skip adjuvant chemotherapy. NCCN BINV-N category 1 for using the 21-gene assay in this population. In women <=50 years, chemotherapy benefits those with RS 16-25, linking genomic and clinical risk.

Source: PMID 29860917

Timeline

  • Publication: 2018 Jul 12

Guideline citations

  • NCCN BREAST